Cetuximab companion diagnostic - BioMarker Strategies
Latest Information Update: 28 Nov 2020
At a glance
- Originator BioMarker Strategies
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Diagnosis) in USA
- 13 Apr 2018 BioMarker Strategies has patent protection for PathMAP functional signaling profiles in China
- 20 Mar 2018 BioMarker Strategies has patent protection for PathMAP® functional signaling profile technology in Canada